GET DAILY SIGNALSLifeStance Health (LFST) Delivers Strong Q3 with +25% Revenue Growth
Key Takeaways
- Revenue rose 25% year over year to $455.9 million, exceeding Wall Street consensus estimates of roughly $431.7 million.
- Diluted earnings per share (EPS) came in at $0.06, double the $0.03 consensus estimate and up from essentially breakeven a year earlier.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 70% to $68.4 million, reaching a 15.0% margin for the second consecutive quarter.
- Net income jumped to $22.4 million from $1.1 million in the prior-year period, while the clinician base grew 11% to 8,863.
- Management raised its full-year 2026 outlook across revenue, Center Margin, and Adjusted EBITDA, citing broad-based operating momentum.
- Investors should note a newly quantified headwind: a phased electronic health record (EHR) transition expected to trim 2027 revenue growth by roughly 1 to 2 percentage points.
Earnings Context and Why It Matters
LifeStance Health Group is one of the nation's largest providers of virtual and in-person outpatient mental healthcare, operating more than 575 centers across 35 states with over 8,800 clinicians. The company has spent recent quarters converting rapid top-line growth into expanding profitability, making each earnings release a key test of its operating leverage. Heading into the third quarter, I was watching whether clinician recruiting, visit volumes, and revenue per visit could sustain momentum built earlier in 2026. This report matters because it shows whether LFST can keep scaling its fixed cost base while continuing to absorb rising demand for mental health services, a trend that has supported the broader outpatient care industry. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, LifeStance reported total revenue of $455.9 million, a 25% increase from $363.8 million in the same period a year earlier. The result topped consensus estimates and was driven by higher visit volumes, improved clinician productivity, and a rise in total revenue per visit. Visit volumes increased 17% to 2.7 million, and total revenue per visit rose 7% to $170, primarily reflecting payer rate increases.
Diluted EPS was $0.06, compared with $0.00 in the prior-year quarter and ahead of the $0.03 consensus estimate. Net income reached $22.4 million, up from $1.1 million a year ago. Adjusted EBITDA grew 70% to $68.4 million, representing 15.0% of revenue, while Center Margin (a non-GAAP measure of revenue less center-level costs) increased 38% to $161.4 million, or 35.4% of revenue.
The company also raised its full-year 2026 guidance: revenue of $1.741 billion to $1.761 billion, Center Margin of $599 million to $613 million, and Adjusted EBITDA of $242 million to $250 million. For the fourth quarter, LifeStance guided to revenue of $446 million to $466 million and Adjusted EBITDA of $56 million to $64 million. From what I see, these numbers reflect solid execution across the board.
Market Reaction and Investor Sentiment
LifeStance shares advanced after the report, with the stock rising about 6% to roughly $15.06 immediately following the release, according to market data. The positive reaction reflected a clean beat on revenue and EPS, a second consecutive quarter of 15% Adjusted EBITDA margins, and an upward revision to full-year guidance. Sentiment was also supported by strong clinical outcomes data published for specialty services treating treatment-resistant depression, where 74% of Spravato patients and 61% of transcranial magnetic stimulation (TMS) patients showed clinically meaningful improvement.
At the same time, the stock entered the print near 52-week highs, leaving limited room for a larger surprise-driven move. Some observers noted that growth is leaning more heavily on pricing as volume metrics moderate, while the newly quantified 2027 EHR headwind gives investors a reason to temper near-term growth assumptions. I’m watching this closely as the market digests the full picture.
Forward Outlook and Key Factors to Monitor
LifeStance enters the fourth quarter with raised full-year targets implying roughly 23% revenue growth for 2026 and Adjusted EBITDA margin expansion of about 3 percentage points year over year. Management reiterated its long-term algorithm of mid-teens revenue growth and continued margin expansion, but offered an early, more cautious read on 2027.
The most important near-term variable is the phased rollout of a new EHR system, which management estimates will reduce 2027 revenue growth by approximately 1 to 2 percentage points and carry meaningful implementation costs. The company plans a state-by-state rollout intended to limit disruption across its clinician base, and it views the new platform as a long-term enabler of patient access and operational efficiency.
Beyond the technology transition, investors should monitor several drivers. Specialty services, including TMS and Spravato for treatment-resistant depression, are tracking toward roughly $70 million in 2026 revenue, up about 40%, and remain a faster-growing segment. Clinician recruiting and productivity, payer reimbursement rates, and the pace of tuck-in acquisitions and new center openings will also shape the growth trajectory. Management signaled a continued cadence of one to two acquisitions per quarter through 2027, providing additional levers for geographic expansion. One thing that stands out is how these factors could influence the path ahead.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating earnings beats like this one. It helps me quickly filter for comparable companies, spot technical patterns, and review AI-driven signals across the sector. This approach keeps my analysis efficient and adds another layer of perspective beyond the headline numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFST's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LFST turned positive on October 22, 2026. Looking at past instances where LFST's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LFST as a result. In 71 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
LFST moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LFST crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +7.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFST advanced for three days, in 227 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 179 of 246 cases where LFST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
LFST broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. LFST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.456) is normal, around the industry mean (204.059). P/E Ratio (95.929) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (3.182) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement